NEW YORK (GenomeWeb) – GenMark Diagnostics announced after the close of the market on Tuesday that it has applied to the US Food and Drug Administration for clearance of its ePlex Blood Culture Identification Gram-Negative (BCID-GN) and ePlex Blood Culture Identification Fungal Pathogen (BCID-FP) panels.

As a result, the firm has now completed submissions for all three of its ePlex molecular multiplex panels designed for the diagnosis and management of bloodstream infections that can lead to sepsis. The panels are being developed on GenMark's ePlex sample-to-answer system.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.